A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
Yup, very true - I'm just very worried that those 300 people wouldn't fully understand what they're signing up for. Need the safety data on the vaccine in any case, which already requires a lot of people - but I guess it depends onwhether we want (a) safety, or (b) efficacy data first. If the latter, challenge trial makes sense.
-
Yes - it's definitely Trumps next trick for sure....
-
He'd push it through - _even_ if we knew it was unsafe or even dangerous. No doubt. And that's bloody terrifying.
-
Enough safety data should be there in the Phase I and II trials - you're right that the Moderna safety data is HIGHLY suspect.
-
2020-07-23 09:06
Kristian G. Andersen
If I were a betting man, I'd put my money on ChAdOx1 and Sinovac - I'd forget anything RNA- or DNA-based for now- it's just too early for those platforms.
-
"fully understand what they're signing up for" - lay it out for them - they might die. We've got a 1000 dying each day just in the US. Yes - some trial participants could die - I think it's less likely with the better treatment regiments -dexy, remdesivir if they get in trouble - give them Ho or Crowe's MAbs.
-
AGree about the RNA/DNA - There are other vectors that could work too - even VSV- the devil we know....
-
True - maybe Ad26 too (I don't know enough about that one). Ad5 does not seem appealing, although I'm pretty sure China will approve it (CanSino).
-
In my mind you definitely want the efficacy data first. If it doesn't work in young and health it won't work in the old and compromised.